Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1569-1576

  Tetef, Merry L ^a   Synold, Timothy W ^a   Chow, Warren ^a   Leong, Lucille ^a   Margolin, Kim ^a   Morgan, Robert ^a   Raschko, James ^a   Shibata, Stephen ^a   Somlo, George ^a   Yen, Yun ^a   Doroshow, James H ^a   Groshen, Susan ^b   Johnson, Kay ^b   Lenz, Heinz Josef ^b   Gandara, David ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; RAZOXANE; ZINC;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DIFFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASMS; RAZOXANE; TIME FACTORS;

EID: 0034895956     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
2. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
3. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
4. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
5. Role of reactive-oxygen metabolism in the cardiac toxicity of the anthracycline antibiotics
6. Metal binding by pharmaceuticals. Part 2. Interaction of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II), and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF 159 and its inactive homologue ICRF 192
7. ICRF-159 versus polychemotherapy in non-small cell lung cancer
8. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy
9. Phase II study of ICRF-159 (NSC- 129943) in advanced colorectal carcinoma
10. Treatment of Kaposi's sarcoma with ICRF-159 (NSC 129943)
11. Phase II study of ICRF-159 in non-Hodgkin's lymphomas
12. Limited activity of ICRF-159 in advanced acute leukemia
13. Phase II trial of ICRF- 159 in previously treated patients with head and neck carcinoma
14. Antitumor activity in a series of bisdiketopiperazines
15. Mode of action of the cytotoxic agent ICRF-159
16. Inhibition of topoisomerase II by antitumor agent bis(2, 6-dioxopiperazine) derivatives
17. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy
18. Phase I study of ICRF-187 using a daily for 3 days schedule
19. Phase I trial of ICRF-187 by 48-hour continuous infusion
20. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
21. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
22. Anthracycline dose intensity: Clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion
23. Pharmacokinetics of (+)-1, 2-di(3, 5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients
24. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed dose doxorubicin
25. The pharmacokinetics of highdose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast cancer patients
26. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp
27. Inhibition of topoisomerase II by antitumor bis(2, 6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors
28. Antineoplastic activity of continuous exposures to dexrazoxane: Potential new role as a topoisomerase-II inhibitor
29. Characterization of the aqueous decomposition products of (+)1, 2-bis(3, 5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis
30. Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids
31. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)
32. Dexrazoxane potentiates the cytotoxic activity of topotecan in a sequence and schedule dependent manner